432 related articles for article (PubMed ID: 28338503)
1. Efficacy and Safety of Crystalline Valsartan/Sacubitril (LCZ696) Compared With Placebo and Combinations of Free Valsartan and Sacubitril in Patients With Systolic Hypertension: The RATIO Study.
Izzo JL; Zappe DH; Jia Y; Hafeez K; Zhang J
J Cardiovasc Pharmacol; 2017 Jun; 69(6):374-381. PubMed ID: 28338503
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Sacubitril/Valsartan (LCZ696) Compared With Olmesartan in Elderly Asian Patients (≥65 Years) With Systolic Hypertension.
Supasyndh O; Wang J; Hafeez K; Zhang Y; Zhang J; Rakugi H
Am J Hypertens; 2017 Nov; 30(12):1163-1169. PubMed ID: 28992296
[TBL] [Abstract][Full Text] [Related]
3. Effects of Sacubitril/Valsartan Versus Olmesartan on Central Hemodynamics in the Elderly With Systolic Hypertension: The PARAMETER Study.
Williams B; Cockcroft JR; Kario K; Zappe DH; Brunel PC; Wang Q; Guo W
Hypertension; 2017 Mar; 69(3):411-420. PubMed ID: 28093466
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of sacubitril/valsartan compared with olmesartan in Asian patients with essential hypertension: A randomized, double-blind, 8-week study.
Huo Y; Li W; Webb R; Zhao L; Wang Q; Guo W
J Clin Hypertens (Greenwich); 2019 Jan; 21(1):67-76. PubMed ID: 30536595
[TBL] [Abstract][Full Text] [Related]
5. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study.
Ruilope LM; Dukat A; Böhm M; Lacourcière Y; Gong J; Lefkowitz MP
Lancet; 2010 Apr; 375(9722):1255-66. PubMed ID: 20236700
[TBL] [Abstract][Full Text] [Related]
6. Long-term (52-week) safety and efficacy of Sacubitril/valsartan in Asian patients with hypertension.
Supasyndh O; Sun N; Kario K; Hafeez K; Zhang J
Hypertens Res; 2017 May; 40(5):472-476. PubMed ID: 27853163
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of sacubitril/valsartan (LCZ696) add-on to amlodipine in Asian patients with systolic hypertension uncontrolled with amlodipine monotherapy.
Wang JG; Yukisada K; Sibulo A; Hafeez K; Jia Y; Zhang J
J Hypertens; 2017 Apr; 35(4):877-885. PubMed ID: 28030431
[TBL] [Abstract][Full Text] [Related]
8. Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF.
Böhm M; Young R; Jhund PS; Solomon SD; Gong J; Lefkowitz MP; Rizkala AR; Rouleau JL; Shi VC; Swedberg K; Zile MR; Packer M; McMurray JJV
Eur Heart J; 2017 Apr; 38(15):1132-1143. PubMed ID: 28158398
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Asian patients with hypertension: a randomized, double-blind, placebo-controlled study.
Kario K; Sun N; Chiang FT; Supasyndh O; Baek SH; Inubushi-Molessa A; Zhang Y; Gotou H; Lefkowitz M; Zhang J
Hypertension; 2014 Apr; 63(4):698-705. PubMed ID: 24446062
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of sacubitril/valsartan in patients with essential hypertension uncontrolled by olmesartan: A randomized, double-blind, 8-week study.
Cheung DG; Aizenberg D; Gorbunov V; Hafeez K; Chen CW; Zhang J
J Clin Hypertens (Greenwich); 2018 Jan; 20(1):150-158. PubMed ID: 29338113
[TBL] [Abstract][Full Text] [Related]
11. Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial.
Solomon SD; Rizkala AR; Gong J; Wang W; Anand IS; Ge J; Lam CSP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; Van Veldhuisen DJ; Zannad F; Zile MR; Desai AS; Shi VC; Lefkowitz MP; McMurray JJV
JACC Heart Fail; 2017 Jul; 5(7):471-482. PubMed ID: 28662936
[TBL] [Abstract][Full Text] [Related]
12. Ambulatory blood pressure response to once-daily fimasartan: an 8-week, multicenter, randomized, double-blind, active-comparator, parallel-group study in Korean patients with mild to moderate essential hypertension.
Lee H; Kim KS; Chae SC; Jeong MH; Kim DS; Oh BH
Clin Ther; 2013 Sep; 35(9):1337-49. PubMed ID: 23932463
[TBL] [Abstract][Full Text] [Related]
13. Systolic Blood Pressure in Heart Failure With Preserved Ejection Fraction Treated With Sacubitril/Valsartan.
Selvaraj S; Claggett BL; Böhm M; Anker SD; Vaduganathan M; Zannad F; Pieske B; Lam CSP; Anand IS; Shi VC; Lefkowitz MP; McMurray JJV; Solomon SD
J Am Coll Cardiol; 2020 Apr; 75(14):1644-1656. PubMed ID: 32192799
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of Pharmacokinetic and Pharmacodynamic Drug-Drug Interaction of Sacubitril/Valsartan (LCZ696) and Sildenafil in Patients With Mild-to-Moderate Hypertension.
Hsiao HL; Langenickel TH; Petruck J; Kode K; Ayalasomayajula S; Schuehly U; Greeley M; Pal P; Zhou W; Prescott MF; Sunkara G; Rajman I
Clin Pharmacol Ther; 2018 Mar; 103(3):468-476. PubMed ID: 28599060
[TBL] [Abstract][Full Text] [Related]
15. Effect of Sacubitril/Valsartan on Exercise-Induced Lipid Metabolism in Patients With Obesity and Hypertension.
Engeli S; Stinkens R; Heise T; May M; Goossens GH; Blaak EE; Havekes B; Jax T; Albrecht D; Pal P; Tegtbur U; Haufe S; Langenickel TH; Jordan J
Hypertension; 2018 Jan; 71(1):70-77. PubMed ID: 29180454
[TBL] [Abstract][Full Text] [Related]
16. Impact of systolic blood pressure on the safety and tolerability of initiating and up-titrating sacubitril/valsartan in patients with heart failure and reduced ejection fraction: insights from the TITRATION study.
Senni M; McMurray JJV; Wachter R; McIntyre HF; Anand IS; Duino V; Sarkar A; Shi V; Charney A
Eur J Heart Fail; 2018 Mar; 20(3):491-500. PubMed ID: 29164797
[TBL] [Abstract][Full Text] [Related]
17. Angiotensin II Receptor-Neprilysin Inhibitor Sacubitril/Valsartan Improves Endothelial Dysfunction in Spontaneously Hypertensive Rats.
Seki T; Goto K; Kansui Y; Ohtsubo T; Matsumura K; Kitazono T
J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 29042424
[TBL] [Abstract][Full Text] [Related]
18. Titration and Tolerability of Sacubitril/Valsartan for Patients With Heart Failure in Clinical Practice.
Du AX; Westerhout CM; McAlister FA; Shanks M; Oudit GY; Paterson DI; Hanninen M; Thomas J; Ezekowitz JA
J Cardiovasc Pharmacol; 2019 Mar; 73(3):149-154. PubMed ID: 30540684
[TBL] [Abstract][Full Text] [Related]
19. Effects of Sacubitril/Valsartan (LCZ696) on Natriuresis, Diuresis, Blood Pressures, and NT-proBNP in Salt-Sensitive Hypertension.
Wang TD; Tan RS; Lee HY; Ihm SH; Rhee MY; Tomlinson B; Pal P; Yang F; Hirschhorn E; Prescott MF; Hinder M; Langenickel TH
Hypertension; 2017 Jan; 69(1):32-41. PubMed ID: 27849566
[TBL] [Abstract][Full Text] [Related]
20. LCZ696, a First-in-Class Angiotensin Receptor-Neprilysin Inhibitor: The First Clinical Experience in Patients With Severe Hypertension.
Kario K; Tamaki Y; Okino N; Gotou H; Zhu M; Zhang J
J Clin Hypertens (Greenwich); 2016 Apr; 18(4):308-14. PubMed ID: 26402918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]